The Carcinoembryonic Antigen Rapid Test is a rapid chromatographic immunoassay for the qualitative detection of CEA in serum, plasma, or whole blood. It is intended as an aid in the assessment and diagnosis of colorectal cancer and other types of cancers, such as pancreatic, stomach, breast, lung, and certain types of thyroid and ovarian cancer.

Zhejiang Orient Gene Biotech Co., Ltd specializes in the R&D, production, and sales of in vitro diagnostic products in the field of high-end medical equipment and devices.
Currently, its main products are POCT instant diagnostic reagents, which are mainly used in the detection of infectious diseases (including COVID-19 detection products), drugs of abuse, fertility, tumor marker and cardiac marker detection, among which infectious disease and drugs of abuse detection are the two core product series of the company.
The company’s sales network has been extended to more than 120 countries and regions, and its overseas sales revenue accounted for 95% in 2019. At present, the company has obtained more than 300 overseas certifications/records, and more than 70 domestic registration/record certificates.